(Date:12/4/2009)... 4 Pamela Bowen, Chief Information... finalist for the "Chief Innovation Officer" Appy ...e power of cloud computing. Appy Award recipients ...alesforce CRM or the Force.com platform in bringin...arketing, partner, service, support or IT organiza...
(Date:12/4/2009)...e pediatric cancers, particularly Ewing sarcomas a... to a new study published online December 4 in the...his study was undertaken because there is limited ...to 20 years) for pediatric cancer patients. , Ka...enter and Blood Disorders Service, Children,s Heal...
(Date:12/4/2009)...esearchers, from the School of Medicine,s Departme...ways by which products of lipid peroxidation and s...etabolized. The pathways were identified by a comb...is. The findings shed new light on the mechanism o...e, also known as "the date rape drug." The manuscr...
(Date:12/4/2009)...urism is a phenomenon that was started by people t...ice of dental work in the US, Canada, and other co...are, people have found that Mexican Dental Vacatio...n. , (PRWEB) December 4, ...ars, Mexican Dental Vacation is seeing their best ...
(Date:12/4/2009)...deral regulators to crack down on abuse of opioid ...y News) -- The makers of 24 different prescription...s with plans to curb the abuse of these opioid dru...nder pressure from U.S. Food and Drug Administrati... fatal overdoses that occur with these medications...
Breaking Medicine News(10 mins):Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Makers of Powerful Painkillers Present Safety Plans 2...ter study shows that an experimental drug lowers p...r tumor growth in men with advanced prostate canc...led. The study, led by researchers at Memorial Slo...rostate cancer eventually build up resistance to t...
...res Renowned Translational Cancer Researchers and ...with Academic and Industry Leaders , , NEW YORK, ...ists will discuss the rapidly changing cancer rese...on Clinical Investigator Symposium. , , The Apr...
...s Sigma as they move from B2B to B2C, encouraging ... treatment. , , ORADELL, N.J., April 8 Sigma Gro...echnologies, the world leader in burn care product...ields and hospitals directly to consumer household...
...April 8 Dialysis Corporation of America (Nasdaq: ...a grant agreement with the University of Cincinna...ll total $265,000 each year, for the next three ye...ration of America a platform from which to support...
...nn. -- A new study conducted at Mayo Clinic report...oses of certain drugs for Parkinson,s disease deve... notably compulsive gambling or hypersexuality. , ...lable on the Mayo Clinic News Blog. , The study ...
... 8, 2009) Middle school youth are engaging in sex... study by researchers at The University of Texas S...y are published in the April issue of Journal of ...ual risk behaviors among middle school students in...
Other Medicine News:Health News:Drug shows activity in men with advanced prostate cancer 2Health News:Drug shows activity in men with advanced prostate cancer 3Health News:Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium 2Health News:Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium 3Health News:Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium 4Health News:Sigma is Named AOR for Water-Jel Technologies, The World Leader in Burn Care Products 2Health News:Dialysis Corporation of America Announces Establishment of Clinical Grant Agreement with the University of Cincinnati, College of Medicine 2Health News:Parkinson's disease medication triggers destructive behaviors 2Health News:Middle school youth as young as 12 engaging in risky sexual activity 2(Date:12/4/2009)..., Md., Dec. 4 Drs. Neal Shore and ...pecific antigen (PSA) recurrence from the addition... recurrence rate in a Phase III pivotal study of F... monthly leuprolide in prostate cancer patients du... patients who received FIRMAGON 240/80 mg/month ha...
(Date:12/3/2009)...RK, Dec. 3 Guidepoint Global, LLC...d the launch of their Sleep Apnea Tracker, a month...jects trends and market share in the worldwide Sle...ptures actual patient usage for 87 different Sleep...15 different equipment providers going back to Jan...
(Date:12/3/2009)...ALE, Calif., Dec. 3 Phar...cal company focused on developing and commercializ...ent of immune mediated diseases and cancer, today ...ce call on, Tuesday, December 8, 2009 at 11:00am E...ic Time) to discuss clinical data regarding its HD...
Breaking Medicine Technology:Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2Waiting Wondering About Radiology Results Irks Patients 60703 1Waiting Wondering About Radiology Results Irks Patients 60703 2Shorter More Intense Radiation OK for Some Breast Cancers 60701 1Shorter More Intense Radiation OK for Some Breast Cancers 60701 2Shorter More Intense Radiation OK for Some Breast Cancers 60701 3Does race income predict prostate cancer outcome 3F 60699 1Does race income predict prostate cancer outcome 3F 60699 2...n., Sept. 22 VION,PHARMACEUTICALS, INC. (OTC Bull...red into an agreement with the Institut Paoli-Calm...er Phase I/II clinical trial of,laromustine (Clore...py in,patients aged 18-60 with previously untreate...nosis based on their cytogenetic profile., The In...
...for Efficacy in Drug Resistant Skin Infections, S...,announced the initiation of Phase 2 testing of th... antibacterial drug TR-701. The multicenter,trial ... once-daily doses,of 200, 300 and 400 milligrams o...fections (cSSSI) for five to seven days of treatme...
Other Medicine Technology:Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients 2Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients 3Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients 4Trius Doses First Patient in Antibacterial Phase 2 Trial 2Kelly Descemet's Membrane Punch
Optec 3500 Vision Tester
Stainless Steel Ruler
Colorado Needle
Medicine Products: